Trial Profile
A Single Arm, Open-label, Multicentre, Phase II Study of Tositumomab and Iodine 131-Tositumomab in Subjects With Indolent Non-Hodgkin's Lymphoma Who Have Previously Received Rituximab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Tositumomab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors GSK
- 10 Aug 2012 Actual patient number changed from 90 to 93 as reported by ClinicalTrials.gov.
- 20 May 2011 Planned end date changed from 1 Apr 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
- 20 May 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.